Nevertheless, PSMA-guided imaging might be a valuable instrument for selecting metastatic BC patients who could benefit from PSMA-targeting RLT; in this setting, more prospective trials are warranted to assess if this novel therapeutic strategy is suitable to enter clinical practice. This evidence concerns the gene FOLH1 and breast cancer.